Prometheus Announces Breakthrough e-Kerosene Pathway to Make Cost-Competitive SAF and Diesel from Electricity and Air
14.1.2026 14:57:00 CET | Business Wire | Press release
Company reveals world’s first 100% electrochemical pathway for producing e-kerosene directly from atmospheric CO2 and renewable electricity without hydrogen, making Fischer-Tropsch obsolete.
Prometheus Fuels today announced its revolutionary new pathway for producing synthetic paraffinic kerosene (the basis for SAF jet fuel and e-diesel) from direct air capture of CO2 and off-grid renewable electricity. The new Prometheus e-kerosene pathway makes Fischer-Tropsch synthesis obsolete, reducing the cost to make e-fuels by more than 80 percent compared to the century-old technology. It is also the first process in history to make kerosene from electricity and atmospheric CO2 without using hydrogen. The kerosene produced is 100 percent carbon neutral. Two independent engineering reviews confirmed demonstration of the new pathway using commercial-scale cells.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114310118/en/

Because the Prometheus e-kerosene pathway operates at ambient temperatures and pressures, it uses much less expensive equipment than the high-temperature, high-pressure Fischer-Tropsch process. This is just one example of several major cost drivers of conventional e-fuel production Prometheus has eliminated with its breakthrough e-kerosene pathway. ©Prometheus Fuels
The announcement follows the company’s recent milestone achievement of completing a one-year pilot-scale demonstration of its DAC-to-fuels technology platform, producing e-methanol at its Titan Forge Alpha pilot facility. The pilot and its operating data were validated by two independent engineering reviews, in November and December of 2025.
For the first time, Prometheus is releasing details of its new 100 percent electrochemical synthetic paraffinic kerosene pathway, which uses CO2 captured from the air using the company’s proprietary “No-Desorb DAC” process. A key breakthrough that made the new kerosene pathway possible is a process the company calls “electrochemical oligomerization.” Oligomerization is the combining of smaller monomers into larger molecules, like hydrocarbons. One example of this is carbon-carbon chain lengthening. In the Fischer-Tropsch process, this chain lengthening occurs due to the high pressures and temperatures that process requires. It is these extreme operating conditions, which require expensive equipment and 24-7, grid-connected power, that keep the cost of Fischer-Tropsch e-fuels permanently high. In contrast, Prometheus has developed the ability to achieve its carbon-carbon chain lengthening using electromagnetic fields and electric currents in water at room temperature and atmospheric pressure. With these ambient operating conditions, the Prometheus process uses equipment that is much less expensive and can be powered by intermittent, off-grid solar, allowing access to the lowest energy input costs.
The new pathway eliminates the major cost drivers of conventional e-fuels systems. It does not desorb CO2 into a pure gas stream; does not use hydrogen; does not rely on high-temperature or high-pressure reactors; and was purpose-built to operate on intermittent off-grid renewable electricity – the cheapest electrons in the world – avoiding the high cost and geographic constraints of being connected to a grid. There is also no need for distillation. Kerosene forms directly in Prometheus’ Faraday Reactor hydrocarbon electrolyzer and self-separates from water, at room temperature and atmospheric pressure, producing finished kerosene fuel. Notably, the Prometheus e-kerosene pathway has linear cost scaling, allowing it to achieve its low costs across a wide range of production scales, from pilot systems to commercial plants.
“Our new kerosene pathway takes e-fuels beyond decarbonization to direct economic competition with oil-based fuels,” said Rob McGinnis, founder and CEO of Prometheus. “Our pathway puts three holy grails of energy within reach: a new source of energy for data centers, limitless low-cost SAF, and unblockadeable fuel logistics for defense. The implications of this new technology – the advantages it creates for energy independence and national security – are profound.”
Until now, Prometheus had shared only high-level descriptions of its technology while it focused on building and securing its patent and trade secret portfolio. With its IP portfolio secure, Prometheus is able to release more details about its technology and competitive advantages in global commodity energy markets.
About Prometheus Fuels
Prometheus is the global leader in fuels made from air and electricity to power AI data centers, factories, ships, vehicles, and aircraft. The company’s patented technology produces carbon neutral fuels that are cost-competitive with commodity fossil fuel prices without subsidies. Designed to run off-grid, Prometheus offers an infinitely scalable source of new energy, transforming intermittent renewable electricity into firm dispatchable 24/7 power, anywhere it is needed. Backed by top-tier investors including Maersk, BMW, and Y Combinator, Prometheus is redefining the future of energy. Learn more at prometheusfuels.com and prometheusfuels.AI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260114310118/en/



Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release
Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release
QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom